Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:
Digital Health FDA Regulation

Drug/Software Combo Platform Coming Soon To US FDA, Gottlieb Says

  • Analysis

Executive Summary

Under new platform, drugs could soon be approved with accompanying software applications that could monitor adverse events or patient compliance without a separate premarket device review.
Table

View full table

Advertisement

Related Content

Medtech Insight
Drug/Software Combos Likely Won't Require Pre-Market Review By US FDA
Pink Sheet
Drug/Software Combos Likely Won't Require Pre-Market Review By US FDA
Pink Sheet
US FDA Mulling Core Criteria For Patient-Reported Outcomes
Pink Sheet
US FDA Preparing For New 'Combination Product Agreement Meetings'
Medtech Insight
US FDA Commish Defends Approach To Apple Approvals
Pink Sheet
US FDA's Digital Health Plan Could Brighten OTC Device Outlook
Pink Sheet
Combo-Product Sponsors Could More Easily Get Device Designation At US FDA
Pink Sheet
US FDA's Gottlieb Touts 'Seamless' Clinical Trials, Worries About Second-To-Market Products
Pink Sheet
US FDA’s Patient Input Guidance Opens Door Wider To Social Media Data Collection
Pink Sheet
From Listening To Advising: The Maturation Of US FDA's Patient-Focused Drug Development Program

Topics

Advertisement
Tags:
Digital Health FDA Regulation
UsernamePublicRestriction

Register

PS124134

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By